{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:40:40Z","timestamp":1778622040444,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"PharmaEssentia Corp"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jfma.2020.09.018","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T13:48:20Z","timestamp":1602856100000},"page":"956-964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C"],"prefix":"10.1016","volume":"120","author":[{"given":"Shih-Jer","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Wei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsien-Hong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gin-Ho","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Wen","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsing-Tao","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sien-Sing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Shun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Chiao","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2020.09.018_bib1","series-title":"Global hepatitis report","year":"2017"},{"key":"10.1016\/j.jfma.2020.09.018_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.vhri.2013.08.001","article-title":"Estimating the incidence and prevalence of chronic hepatitis C infection in Taiwan using back projection","volume":"3","author":"McEwan","year":"2014","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.jfma.2020.09.018_bib3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/infdis\/162.4.817","article-title":"Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience","volume":"162","author":"Chen","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2020.09.018_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jmv.1890440114","article-title":"Genotype distribution of hepatitis C virus infection in Taiwan","volume":"44","author":"Wu","year":"1994","journal-title":"J Med Virol"},{"key":"10.1016\/j.jfma.2020.09.018_bib5","first-page":"605","article-title":"The genotypes of hepatitis C virus in patients with chronic hepatitis C virus infection in southern Taiwan","volume":"12","author":"Yu","year":"1996","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jfma.2020.09.018_bib6","doi-asserted-by":"crossref","first-page":"10S","DOI":"10.1016\/S0002-9343(99)00374-5","article-title":"Natural history of hepatitis C","volume":"107","author":"Seeff","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.jfma.2020.09.018_bib7","first-page":"211","article-title":"Hepatitis C and liver transplantation","volume":"13","author":"Tsoulfas","year":"2009","journal-title":"Hippokratia"},{"key":"10.1016\/j.jfma.2020.09.018_bib8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa066403","article-title":"Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3","volume":"357","author":"Shiffman","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2020.09.018_bib9","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2010.06.066","article-title":"Albinterferon Alfa-2b was not inferior to pegylated interferon-\u03b1 in a randomized trial of patients with chronic hepatitis C virus genotype 1","volume":"139","author":"Zeuzem","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2020.09.018_bib10","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1053\/j.gastro.2010.06.062","article-title":"Albinterferon Alfa-2b was not inferior to pegylated interferon-\u03b1 in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3","volume":"139","author":"Nelson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2020.09.018_bib12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gut.2006.102558","article-title":"A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C","volume":"56","author":"Yu","year":"2007","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.jfma.2020.09.018_bib13","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jfma.2020.04.003","article-title":"Taiwan consensus statement on the management of hepatitis C: part (I) general population","volume":"119","author":"Yu","year":"2020","journal-title":"J Formos Med Assoc"},{"issue":"7","key":"10.1016\/j.jfma.2020.09.018_bib14","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jfma.2020.04.002","article-title":"Taiwan consensus statement on the management of hepatitis C: Part (II) special populations","volume":"119","author":"Yu","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2020.09.018_bib15","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"issue":"Suppl 3","key":"10.1016\/j.jfma.2020.09.018_bib16","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1093\/infdis\/jiu057","article-title":"Natural history and management of hepatitis C: does sex play a role?","volume":"209","author":"Baden","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jfma.2020.09.018_bib17","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/MEG.0b013e32834ae863","article-title":"Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response","volume":"23","author":"Floreani","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jfma.2020.09.018_bib18","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1053\/j.gastro.2010.12.027","article-title":"Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C","volume":"140","author":"Villa","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2020.09.018_bib19","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620304599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620304599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:43:18Z","timestamp":1760539398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664620304599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0929664620304599"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2020.09.018","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2020.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}